Category Archives: Substance Abuse and Mental Health Services Administration (SAMHSA)

International Overdose Awareness Day

THE BIZZELL GROUP SUPPORTS INTERNATIONAL OVERDOSE AWARENESS DAY

Lanham, MD – The Bizzell Group (Bizzell) – International Overdose Awareness Day is a global event held on August 31st each year and aims to raise awareness of overdose and reduce the stigma of drug-related deaths. It also acknowledges the grief felt by families and friends remembering those who have met with death or permanent injury because of drug overdose.

Opioid addiction is a problem with far reaching costs to individuals, families, communities, and to society. According to the American Society for Addiction Medicine, drug overdose is the leading cause of accidental death in the United States, with 52,404 lethal drug overdoses in 2015.  Opioid addiction is driving this epidemic, with 20,101 overdose deaths related to prescription pain relievers, and 12,990 overdose deaths related to heroin in 2015. The government’s annual drug death statistics for 2016 will not be available until the late 2017, but experts predict sharp increases driven by the worsening opioid crisis.

Bizzell’s work includes projects that support the treatment of addiction, drug use, drug misuse, and overdose.  Through the firm’s work with the Substance Abuse and Mental Health Services Administration (SAMHSA), Bizzell offers workforce competency efforts for pain management and addiction professionals with the development and implementation of multifaceted initiatives and strategies to address opioid use disorder and related conditions.

Bizzell also offers training for medical and other professionals through a 7-hour workshop, Effective Use of Medication Assisted Treatment in an Opioid Dependent Population. The goal of the training is to provide the clinical and administrative staff of opioid treatment programs (OTPs) with up-to-date information and guidance in the treatment of opioid use disorders, including the effective use of the currently approved medications, such as methadone, buprenorphine, and naltrexone.

“The devastating role that addiction and substance use disorders play in our society cannot be overstated. If you are not personally affected by alcohol, tobacco, prescription drugs containing opiates or other drugs, then I’m certain that you know someone who is. Substance use disorders do not discriminate; no demographic or group is immune or exempt from it. It affects us all.”

– Dr. Anton Bizzell, President and CEO


International Overdose Awareness Day will be marked throughout the world with various public events and presentations. In Washington, D.C., Dr. Nzinga Harrison’s lecture Your Community. Your Conversation, will take place at Howard University Hospital Tower Auditorium, 2041 Georgia Ave NW, from 2:00 pm – 5:00 pm on Thursday, August 31st.

Bizzell Awarded Three SAMHSA IDIQ Domains

The Bizzell Group  (Bizzell) is excited to continue its successful partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) on the SAMHSA Indefinite Delivery Indefinite Quantity (IDIQ) contract through 2022. The firm was awarded three domains as a prime contractor on the IDIQ contract, and teamed with larger firms who were successful on additional domains. The contract is designed to assist SAMHSA in achieving its goal of reducing the impact of substance abuse and mental illness in America’s communities.

As a prime contractor, Bizzell, along with our partners, will provide assistance in three separate domains (Domain III, Domain V and Domain VI):

Domain III—Policy Analysis and Program Related Projects: Bizzell will assist with policy analysis, regulatory policy, developing programs and program support by organizing focus groups and consultations that will shed light on mental illness and substance use disorders, healthcare and behavioral health disparities as well as other health related topics.

Domain V—Technical Assistance and Training Projects: With Domain V, Bizzell will provide technical assistance and training courses for a wide range of topics including needs assessment, program planning, science-based approaches to prevention and treatment, payment and financing strategies, including managed care, disparities and culturally appropriate/responsive practice, trauma, health information technology, performance measurement, evaluation, and clinical and medical programs, practices and research.

Domain VI—Planning, Implementation and Report Support Projects: The focus of Domain VI is to plan and support multiple concurrent events and activities through the entire planning and logistical support lifecycle.

Aside from the three domains that Bizzell was awarded as a prime, the firm will also provide services to SAMHSA on two additional domains as a subcontractor to larger firms.

Domain I—Feasibility, Pilot, and Evaluation Projects: On Domain I, Bizzell employees will assist the prime contractor and SAMHSA on executing feasibility studies that will determine if an organizational activity, treatment service, strategy, survey or statistical study will work as intended. Feasibility is followed by the Pilot, which will assess whether the results of a feasibility study can be successfully scaled under a broader range of circumstances. The final portion is Evaluation, which will measure relevant aspects of program performance.

Domain IV—Communication Projects: Bizzell employees will assist with conceptualizing, planning, researching, designing, implementing and evaluating the effectiveness of communications projects that will increase awareness and educate stakeholders about SAMHSA’s mission to reduce the impact of substance abuse and mental health on America’s communities.

Bizzell CEO Appointed to CSAP National Advisory Council

In recognition of his extensive expertise in substance abuse prevention and treatment, Anton Bizzell, M.D., CEO of The Bizzell Group (Bizzell), has been appointed by the Secretary of the U.S. Department of Health and Human Services (HHS) to serve on the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) National Advisory Council. Dr. Bizzell’s appointment is effective through November 2018.

CSAP leads the development of national substance abuse prevention policies and programming, promotes the adoption of proven, science-based substance abuse prevention approaches and helps states and communities build their capacity to implement these approaches. As a member of the CSAP National Advisory Council, Dr. Bizzell will support this mission by making recommendations on agency and center activities and policies, in addition to reviewing grant and cooperative agreement submissions. “It’s a great honor and responsibility to work at a national level to help states and communities find proven and practical ways to prevent substance abuse and reduce the impact this disease has on individuals, families and communities,” said Dr. Bizzell.

Since earning his Doctorate in Medicine from the University of Virginia, Dr. Bizzell has spent the majority of his career working to improve access and quality of care issues for people experiencing substance abuse, mental illness or complicating health issues. He has more than 20 years of combined clinical, research, health services, policy and management experiences with various private and public organizations, including his service as a Medical Officer at both the National Institute on Alcohol Abuse and Alcoholism, NIH, and the Center for Substance Abuse Treatment, SAMHSA. Dr. Bizzell has also provided leadership to projects of national significance including CSAP’s Prevention Fellowship Program, SAMHSA’s Federal Drug Free Workplace Technical Support contract, and SAMHSA’s Prescription Drug Misuse and Abuse project.

Bizzell Supports HBCU Campus Dialogue on Prescription Drugs

The Bizzell Group  (Bizzell) supports The National Council on Patient Information and Education (NCPIE) with its recruitment of students, staff, and faculty from Historically Black Colleges and Universities (HBCUs) for an open dialogue on prescription drugs. The event LET’S TALK ABOUT IT: Prescription Drug Use and Its Side Effects is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA).

The groups will discuss current campus trends, explore beliefs about substance abuse and addiction, and discover on- and off-campus prevention, treatment and recovery services.  There will be two sessions – one for faculty and staff on Friday, March 28th and one for students on Saturday, March 29th.

Research suggests that there are varied motivations for prescription drug abuse among teens and college-aged students, including getting high, coping with pain or sleep problems and in some instances improving or enhancing cognition.  These behaviors are risky as medications prescribed by doctors are assumed to be safe, however abuse of these drugs can have harmful health effects, including overdose.  This discussion seeks to open a dialogue among students and health professionals to combat myths and generalizations about prescription drug misuse.

Faculty and staff are encouraged to RSVP by March 21, 2014 for the event on March 28th from 10 am – 3 pm.  Students should RSVP by March 25, 2014 for the event on March 29th from 11 am – 4 pm. Interested participants should RSVP by calling 202.806.7706 or emailing dm_barnes@howard.edu.

Both sessions will take place at The Gallery Lounge in the Blackburn Center at Howard University, 2400 Sixth Street, NW, Washington, DC 20059. Participants are advised that this counts as a community service activity and resume-builder.  Limited seating is available. Lunch and parking will be provided.

To learn more about the issue, visit: Taking Action to Prevent & Address Prescription Drug Abuse:  A Resource Kit for America’s College Campuses and www.recoveryopensdoors.org